This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M05.3 | Special Copayment Reduction: V223 (severe intractable disease, 5 years) |
| B. Synonyms | Rheumatoid pericarditis, rheumatoid myocarditis, rheumatoid neuropathy, rheumatoid endocarditis, rheumatoid cardiomyopathy |
| C. Adult onset | Adult onset: very high — extra-articular involvement occurring in long-standing severe RA; median age at onset 50s–70s. |
| 1. History | See main text |
| 2. Causes | See main text |
| 3. Genetics | See main text |
| 4. General epidemiology | See main text |
| 5. Pathophysiology | See main text |
| 6. Symptoms | See main text |
| 7. Signs | See main text |
| 8. Screening | See main text |
| 9. Diagnosis | See main text |
| 10. Treatment | See main text |
| 11. Prognosis | See main text |
| 12. Prevention | See main text |
| 13. References | See main text |
Rheumatoid arthritis (RA) was named by Garrod in 1858, and the treatment paradigm developed with the introduction of corticosteroids in the 1940s-50s, the establishment of MTX in the 1980s, and the biologic revolution of the 2000s. The joint ACR/EULAR classification criteria were established in 2010.
M05.3 classifies RA phenotypes involving organs such as the heart, nervous system, and eyes, other than rheumatoid lung disease (M05.1) and vasculitis (M05.2). Before the introduction of corticosteroids in the 1950s–70s, these systemic complications were more frequently fatal. At present, the occurrence of systemic complications is decreasing with aggressive DMARD/biologic treatment.
The cause of RA is the combined action of genetic predisposition such as the HLA-DRB1 shared epitope, PTPN22, and PADI4; environmental factors such as smoking and periodontal infection; and breakdown of immune tolerance to citrullinated autoantigens. TNF-α, IL-1β, IL-6, and IL-17 are the main inflammatory cytokines.
Severe seropositive RA (high RF/ACPA), inadequate control of active arthritis, smoking, HLA-DR4, and long disease duration increase the risk of systemic complications. Immune complexes and autoantibodies deposit in the blood vessels and tissues of each organ, causing various types of organ damage.
Carrying the HLA-DRB1 shared epitope (DRB1*04:01, *04:04, *01:01) increases the risk of ACPA-positive RA several-fold. PTPN22 R620W, PADI4 (East Asians), STAT4, CTLA4, and CCR6 are susceptibility genes.
RA prevalence is 0.5-1% worldwide and about 0.7-1% in Korea. It is 2-3 times more common in women than in men and occurs most often in the 40s-60s. Prognosis has improved markedly since the introduction of biologics and JAK inhibitors.
The frequency of systemic complications of RA (M05.3) is decreasing with improvements in modern RA treatment. Pericardial involvement is found in 30–50% of RA patients by autopsy criteria, but is clinically significant in fewer than 10%. Neuropathy appears clinically in about 1–5%.
ACPA/RF formation in the preclinical stage → synovial deposition of immune complexes and complement activation → chronic synovial inflammation (TNF-α, IL-1β, IL-6, IL-17) → RANKL-mediated osteoclast activation (bone erosion) → cartilage loss by MMPs.
Pericardium: immune complex deposition, rheumatoid granuloma formation. Myocardium: autoantibody-mediated myocardial injury, amyloid deposition (secondary). Nervous system: vasculitis, atlantoaxial instability (cervical vertebrae 1–2), carpal tunnel syndrome (nerve compression due to synovial thickening). Eye: involvement of scleral and episcleral vessels, keratoconjunctivitis sicca (with Sjögren).
In addition to polyarthritis symptoms, symptoms appear according to the organ involved. Pericarditis: chest pain (worse with breathing and position change), friction rub. Myocarditis/cardiomyopathy: dyspnea, edema, heart failure symptoms. Neuropathy: abnormal sensation of the hands and feet (compression neuropathy such as carpal tunnel syndrome, mononeuritis multiplex). Eye involvement: redness, eye pain, decreased vision (scleritis, episcleritis, corneal melt). Atlantoaxial instability (subluxation of cervical vertebrae 1–2): neck pain, headache (occipital), sensory and motor disturbance of the upper limbs.
Pericardial friction rub, edema and tachycardia (in myocarditis), scleral injection and nodules (scleritis), distal wrist and finger paresthesia (carpal tunnel syndrome), asymmetric nerve damage (mononeuritis multiplex). Tests: electrocardiogram, echocardiography (pericardial effusion/thickening), chest X-ray, nerve conduction study, ophthalmologic slit-lamp examination, cervical spine MRI (assessment of atlantoaxial instability).
When new cardiac, neurologic, or ophthalmologic symptoms appear in long-standing RA, screening tests for the relevant organ are performed. In RA patients with symptoms of cervical instability (neck pain, upper limb neurologic symptoms), cervical spine MRI or flexion/extension X-rays are performed. For carpal tunnel syndrome screening, Phalen's test and Tinel's sign are assessed.
Meets the 2010 ACR/EULAR RA classification criteria + findings confirming organ involvement. Pericardium: echocardiography (effusion, thickening), electrocardiogram (ST-T changes). Nerve: EMG/NCS (nerve conduction study). Eye: ophthalmologic slit-lamp examination (scleritis, episcleritis). Cervical instability: cervical spine X-ray (flexion/extension), MRI. Exclusion of other causes for each organ involvement is essential.
T2T principle: Target clinical remission by DAS28. csDMARD: MTX 15-25 mg/week (first line). bDMARD: anti-TNF (etanercept, adalimumab, etc.), abatacept, rituximab, tocilizumab/sarilumab. tsDMARD: JAK inhibitors (tofacitinib, baricitinib, upadacitinib). Steroids are used at low dose for a short period when inducing remission.
Additional treatment is needed according to each organ involved. Pericarditis: steroids, NSAIDs. Myocarditis: immunosuppressants (steroids, MMF). Neuropathy (compression): carpal tunnel decompression. Neuropathy (vasculitis): steroids, CYC. Scleritis: steroid eye drops, systemic immunosuppression. Atlantoaxial instability: cervical collar, and in severe cases surgery (occipitocervical fusion).
Since the introduction of biologics, functional outcomes and mortality in RA have improved markedly. Early aggressive treatment (window of opportunity) is key to determining long-term prognosis. Poor prognostic factors: high ACPA/RF titers, polyarticular involvement, early bone erosion.
Pericarditis has a good prognosis with treatment. Cardiomyopathy is poor. Atlantoaxial instability, if it progresses without surgical management, carries a risk of serious paralysis due to spinal cord compression. Scleritis can preserve vision with appropriate treatment, but corneal melt requires emergency treatment.
Smoking cessation is the key to preventing ACPA-positive RA. Prevent joint damage with early diagnosis and aggressive DMARD treatment. Tuberculosis screening is essential before starting biologics. Pneumococcal, influenza, and herpes zoster vaccinations are recommended.
To prevent cervical instability, protection of the cervical spine during general anesthesia is important in RA patients. Preoperative cervical spine X-rays (flexion/extension) should be performed to assess instability in RA patients.